CA-SENTRY
30.11.2022 16:01:37 CET | Business Wire | Press release
Sentry, the leader in developer-first application monitoring, today announced it has acquired Codecov, the leading dedicated code coverage reporting solution, providing developers with actionable insights into their workflow. The acquisition expands Sentry’s product offering for development teams to improve code quality and velocity even earlier in the development life cycle, helping to accelerate remediation and enabling the delivery of better end-user experiences.
“Our mission has always been to empower developers to ship high quality code, faster than anyone else through context and insights, versus dashboards and tools that frankly weren’t built for resolution,” said Milin Desai, CEO of Sentry. “The Codecov team shares this singular focus – and enables us to offer developers even more comprehensive insight into their application’s code quality earlier in the development cycle.”
Codecov is the leading dedicated code coverage solution, which helps thousands of development teams at companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently ship stable code. Similar to Sentry, Codecov works within developers’ existing workflows for software development, providing feedback, insight, and ownership over the quality of code regardless of platform, language, or CI/CD tooling. With the acquisition, Sentry customers will benefit from insights and protection over their code quality both pre- and post-deployment.
"At Lyft, we want to help our developers reliably ship code as fast as possible by providing an environment that allows them to feel confident to make and ship changes in code," said Jun Li, Staff Software Engineer at Lyft. "Codecov provides a source of truth for our teams. It reduces friction as it is flexible enough to fit into any language and CI/CD so engineers can see the impact and dig deeper into code changes, all in one place. The implementation of Codecov has improved the overall developer experience and we're seeing more and more adoption of it across our teams.”
“From day one, our primary focus has been on using tools like code coverage to help developers ship quickly and reliably,” said Jerrod Engelberg, CEO of Codecov. “There’s an obvious alignment between Sentry and Codecov in how we empower developers to feel confident in making and shipping changes. We are climbing the same summit of software reliability from opposite sides, and with this, our customers new and old will experience faster development cycles, quicker discovery and remediation of bugs, and an overall better developer experience. ”
Codecov providing intelligent code coverage furthers Sentry’s commitment to addressing the evolving needs of software developers who are using tooling that is not purpose-built for their workflows or their most pressing problems. The addition of Codecov, along with Sentry’s other recent investments will serve to evolve application monitoring for software developers everywhere.
Codecov’s talented and experienced team, including co-founders Jerrod Engelberg and Eli Hooten, will join the Sentry team.
Read the Sentry and Codecov blogs to learn more about how the companies will work together to bring a new level of actionable insight directly into the developer’s workflow.
About Sentry
For software teams, Sentry is essential for monitoring application code quality. From Error tracking to Performance monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble, or LinkedIn.
About Codecov
Codecov is the leading dedicated code coverage reporting solution focused on helping developers quickly ship reliable code while helping engineering teams save time and improve the overall developer experience. The company helps thousands of development teams at some of the world’s largest companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently deliver stable and bug-free code with highly integrated tools to surface coverage insights where they are needed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
